GMP Support Assistant(s)

Job description:

We are at the centre of the rapidly growing cell and gene therapy sector. We deliver life-changing therapies to patients, and so can you.

We are currently recruiting for GMP Support Assistants to join the Manufacturing Support team.

The purpose of this role is work as part of a team in the day-to-day production support activities, to support process continuity in the adherence to the production schedule whilst maintaining GMP, safety and environmental compliance.

OXB’s Manufacturing Team is responsible for the production and aseptic fill and finish of vectors, for our clients and partners, to Good Manufacturing Practice (GMP) standard.

Your responsibilities in this role would be:

• Working as part of a team to achieve the production support schedule with minimal disruption to other activities within the facility.


• Maintaining the GMP compliance of the facility through regular cleaning, material transfer and waste removal.


• Supporting and maintaining the daily, weekly and monthly cleaning activities.


• Performing all work within the manufacturing facility in compliance with the facilities health and safety and GMP procedures.

We are looking for:

• GCSEs, and/or previous experience in a similar environment.


• Experience in a healthcare or laboratory setting would be beneficial.


• Basic computer skills using Microsoft Office environment.


• Good communication skills both written and orally.


• Ability to manage time effectively, being able to plan and complete work to schedule.


• High level of organisation and motivation with excellent attention to details.


• Familiarity with working in an environment requiring high levels of reliability, integrity and confidentiality.

About Us:

OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise.

What’s in it for you:

• Highly competitive total reward packages


• Wellbeing programmes


• Development opportunities


• Welcoming, friendly, supportive colleagues


• A diverse and inclusive working environment


• Our values are: Responsible, Responsive, Resilient, Respect


• State of the art laboratory and manufacturing facilities

We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment and teamwork, and so can you.

Collaborate. Contribute. Change lives

We offer:

Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).

Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.